Professional Marketing: Novartis, Epocrates, Cegedim Dendrite and SK&A Information Services

Share this article:
Novartis launched schizophrenia med Fanapt to US physicians, following a May 2009 approval. In October, Novartis acquired US and Canadian commercialization rights to the pill from Vanda, which retains ex-US marketing rights. A long-acting injectable (depot) formulation is being developed.

Mobile clinical-software outfit Epocrates hired Geoffrey Rutledge, MD, PhD, as chief medical officer and EVP, product development. Rutledge, who has held senior-management roles with WebMD and First Consulting Group, will oversee Epocrates' medical-information team and lead the development of new products.

CRM firm Cegedim Dendrite acquired healthcare data provider SK&A Information Services for an undisclosed sum. SK&A maintains a telephone-verifiable database of contact records used by pharma clients for commercial planning and operations. The firm will be branded as SK&A, A Cegedim Company.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions